Article
A mammalian two-hybrid system for adenomatous polyposis coli-mutated colon cancer therapeutics.
Cancer research - 1 Feb 2001
Wakita K, Tetsu O, McCormick F
Abstract excerpt
Colon cancer cells frequently lose expression of the tumor suppressor adenomatous polyposis coli (APC). As result, beta-catenin accumulates and activates transcription of Tcf-responsive genes. Here we describe a novel mammalian two-hybrid system that selectively kills APC-mutated cells. This system consists of GAL4/beta-catenin, VP16/Tcf4, and a gene that is transcribed when GAL4 and VP16 associate. In...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
